Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
نویسندگان
چکیده
منابع مشابه
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.
The high complete remission rate with first-line combined fludarabine, cyclophosphamide, and rituximab (FCR) begs the question of the value of minimal residual disease (MRD)-negative status as a treatment end point. We report on 237 patients with chronic lymphocytic leukemia who received first-line FCR. MRD was prospectively assessed by 4-color flow cytometry in bone marrow after course 3 and a...
متن کاملVenetoclax Yields Strong Responses in CLL.
Results from an international phase II study show that the investigational BCL2 inhibitor venetoclax is effective in patients with chronic lymphocytic leukemia and the chromosome 17p deletion, whose prognosis is particularly poor. Venetoclax yielded high and durable responses in this population, including several complete remissions.
متن کاملMeasure for measure: minimal residual disease in CLL.
Measuring minimal residual disease (MRD) to detect 1 or fewer CLL cells in 10 000 normal leukocytes has consistently shown correlation with long-term clinical outcomes when examined in the context of prospective clinical trials. Substantial international effort has provided a sound scientific foundation establishing valid and reproducible methods in flow cytometry and polymerase chain reaction–...
متن کاملIdelalisib, ibrutinib show benefits in CLL.
challenging in general, not only for children’s cancers,” says Chesler. “To encourage commercial development, the EMA should consider creative and more robust ways of working with pharma, academia, and government to make the PIP scheme more effi cient.” The FDA and the EMA already share information and communicate regularly about promising drugs, says Reaman. “It’s possible for the FDA and the ...
متن کاملFDA grants accelerated approval for ibrutinib for CLL.
The US Food and Drug Administration (FDA) on Wednesday granted accelerated approval for the expanded use of ibrutinib, marketed as Imbruvica, for chronic lymphocytic leukemia (CLL) patients who have previously received at least one therapy. This approval was based on a phase 1b-2 open-label, multicenter study that was designed to determine the safety, efficacy, pharmacokinetics, and pharmacodyn...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood Cancer Journal
سال: 2021
ISSN: 2044-5385
DOI: 10.1038/s41408-021-00429-z